Correction to: BMC Urol (2020) 20:139 https://doi.org/10.1186/s12894-020-00689-0

In the original publication of this article [1] there were several errors in Table 1 related to the values for Disease status (nmCRPC and mCSPC).


In this correction article the correct and incorrect values are shown.


Table 1 The correct and incorrect values

Incorrect

Correct

Disease status, n

Disease status, n

nmCRPC

55

–

–

55

nmCRPC

34

–

–

34

mCSPC

–

51

–

51

mCSPC

–

28

–

28

Furthermore, the Time-to-event analyses section has several errors with the decimal values/rounding of numbers, the incorrect and correct information is shown below

Incorrect

Correct

66 days

66.0 days

45 days

45.0 days

52 days

52.0 days

38 days

38.0 days

82 days

82.0 days

In the global population of the SPARTAN study, skin rash of any grade resolved for 81% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100 days (Supplementary Table 2)

In the global population of the SPARTAN study, skin rash of any grade resolved for 80.6% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100.0 days (Supplementary Table 2)

100 days

100.0 days

35 days

35.0 days

37 days

37.0 days

66 days

66.0 days


Further errors were detected, specifically under the section Management of Rash. This Correction article shows the incorrect and correct sentences. It was highlighted that some of the values on Table 3 were also incorrect. This Correction article shows the correct Table 3. The original article has been updated.


Incorrect:


Oral antihistamine was the most common (25/35 [71.4%]), followed by systemic and topical corticosteroids (18/35 [51.4%] and 15/35 [42.9%], respectively) (Table 3).


Correct:


Topical corticosteroid was the most common (27/35 [77.1%]), followed by oral antihistamine and systemic corticosteroid (18/35 [51.4%] and 3/35 [8.6%], respectively) (Table 3).

Table 3 Rash management Target population: Safety
Full size table

In the Discussion section:


Incorrect:


This could be attributed to the more frequent use of oral antihistamines (71.4%) and systemic corticosteroids (51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: antihistamines, 36.5%; systemic corticosteroids, 18.5%).


Correct:


This could be attributed to the more frequent use of topical corticosteroids (77.1%) and oral antihistamines (51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: topical corticosteroids, 37.8%; antihistamines, 36.3%.